复发性或转移性头颈癌患者双月一次使用西妥昔单抗的原理与预算影响
在复发性或转移性头颈鳞癌中,西妥昔单抗常规每周给药。该研究从意大利社会视角构建预算影响模型,比较每两周一次500 mg/m2方案与每周一次250 mg/m2方案,结果显示每两周一次50%剂量方案可降低成本,其中大部分为间接成本。
要点
- 每两周一次500 mg/m2西妥昔单抗50%剂量方案较每周方案降低成本。
- 成本降低中70%归因于间接成本。
- 简化方案可减少卫生系统直接成本和社会间接成本。
核心结论
- 该简化方案可降低卫生系统直接成本和社会间接成本。
研究设计与样本
- 基于Excel的预算影响模型,比较每周100%给药250 mg/m2与每两周一次50%或100%给药500 mg/m2两种场景。
主要发现
- 每两周一次50%剂量场景下,计算成本降低347 000欧元,其中70%归因于间接成本。
- 4个月后成本降低增至694 000欧元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy. METHODS: A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m2 to an every-other-week (EOW) administration at 50% or 100% with a dose of 500 mg/m2 . RESULTS: In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months. CONCLUSIONS: In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).
引用
- Mennini FS, Marcellusi A, Fabiano G, et al. Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. Head Neck. 2019. PMID: 30680828. doi:10.1002/hed.25481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。